Study checks if stopping a drug made polyps grow faster
NCT ID NCT04674228
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study reviewed medical records of 42 people with familial adenomatous polyposis (FAP) who had previously taken the drug erlotinib. Researchers wanted to see how quickly the disease progressed after the drug was stopped. The goal was to better understand what happens when treatment ends.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
42 people
The number who actually took part.
- Started
-
May 2021
- Finished
-
May 2022
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants in MAY2016-07-01 Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated with Familial Adenomatous Polyposis
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * MAY2016-07-01 study participants for whom medical records are available and accessible Exclusion Criteria: * MAY2016-07-01 study participants who have opted out of medical records reviews or for whom consent for medical record review cannot be confirmed/documented
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Familial adenomatous polyposis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a freezing balloon zap away precancerous gut growths?
- Gut bacteria may influence polyp risk in inherited colon condition
- Could a common drug curb polyps in teens with rare genetic condition?
- Can pelvic floor exercises help pouch patients regain control?
- New drug E7386 tested for tough cancers
- Large study looks at how a 25-Gene cancer test affects patients and families